Contact UsInvestorsCareersMediaScienceContact Us

Pfizer Canada and BioNTech initiate rolling submission to Health Canada for COMIRNATY in children 6 months to < 5 years of age


June 23, 2022 – Pfizer Canada and BioNTech today filed a Supplemental New Drug Submission (sNDS) with Health Canada for use of COMIRNATY (Pfizer-BioNTech COVID-19 Vaccine) to prevent COVID-19 in children 6 months to < 5 years of age.

In Canada, COMIRNATY is currently approved for use in individuals aged 5 and older. Canadians may find more information about the vaccine at Canadian Health Care Professionals can visit for more information.

COMIRNATY (Pfizer-BioNTech COVID-19 Vaccine), which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in Canada, the United States, the European Union and the United Kingdom, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.

For Further Information 

Corporate Affairs Canada 

1-866-9PFIZER (1-866-973-4937)

[email protected]

About UsOur ProductsHelping Communities Our Voice Suppliers Distribution ChannelPfizer WorldwideMedia CentreTerms Of Use Careers Healthcare ProfessionalsContact UsPrivacy PolicyCopyright © Pfizer Canada 2022 All rights reserved. The information is intended only for residents of Canada. ® Pfizer Inc, used under license